MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC

A method of treating cancer in a subject comprising the steps of:

• (a) administering to the subject a population of modified NK-92 cells having antibody-dependent cell-mediated cytotoxicity (ADCC), wherein the population of modified NK-92 cells comprise heterologous nucleic acid molecules comprising a nucleic acid sequence with at least 90% identity to CD16 (SEQ ID NO:3) and a nucleic acid sequence with at least 90% identity to IL-2 (SEQ ID NO:5), wherein greater than 90% of the cells in the population of cells express CD56, CD16, CD54, and NKp30 and less than 5% of the cells in the population of cells express CD3, and wherein the nucleic acid molecules comprise from 5′ to 3′ a sequence encoding CD16, an IRES sequence, and a sequence encoding IL-2;
• and
• (b) administering to the subject an antibody,
• wherein the administering treats the cancer in the subject.